Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2016 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Executive Vice President and Chief Business Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 at 9:20 AM Eastern Standard Time.
The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or directly at http://wsw.com/webcast/leerink26/fprx. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe, Investor Relations 415-365-5737 [email protected]
